Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dosulepin→

Dosulepin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
113-53-1
Molecular formula
C19H21NS
Molecular weight
295.44 g/mol
Drug class
Tricyclic antidepressantnon-selective monoamine reuptake inhibitor
Mechanism of action
Inhibits neuronal reuptake of noradrenaline and 5-hydroxytryptamine, with a greater effect on noradrenaline; also inhibits dopamine uptake. It has central and peripheral anticholinergic and antihistaminic activity.
Indications / reported uses
  • Treatment of symptoms of depressive illness, particularly where an anxiolytic effect is also required; UK product information restricts use to patients intolerant of or unresponsive to alternative options because of serious toxicity in overdose

Sources: UK SmPC (updated 24 Mar 2026) · UK SmPC (updated 10 Nov 2026) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dosulepin Environmental Risk Assessment (ERA) (the Dosulepin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.